You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care
SBC: PASCALL Systems, Incorporated Topic: 106Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
SBC: CELDARA MEDICAL, LLC Topic: NIAIDPROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair
SBC: Pioneer Neurotech Inc. Topic: 106Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBIDespite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PARCA (a digital tool) to improve Justice and Health
SBC: Q2I, LLC Topic: NIDAPROJECT SUMMARY/ABSTRACT Nearly 4.4 million individuals are on community supervision in the United States, with the majority (about 80%) being supervised under probation.1 Justice involved persons (JIPs) have a 474% increased lifetime experience with heroin, a 303% increased use of OxyContin in the last 12 months, and a 256% increased use in pain medication in the last 12 months, compared to the g ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Assessment of Deep Learning Classification Methods for Parkinsonism
SBC: AUTOMATED IMAGING DIAGNOSTICS LLC Topic: 108SUMMARY The growth rate in the number of people diagnosed with Parkinsonism is substantial. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently diagnosed. By 2040, there will be between 12-14 million people diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and p ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a virtual reality guided acupuncture imagery treatment for Chronic low back pain
SBC: MASSACHUSETTS NEURO TECHNOLOGY, INC. Topic: NCCIHProject Summary Low back pain (LBP) is one of the most common reasons for physician visits in the USA. A substantial number of chronic LBP (cLBP) patients do not adequately respond to current treatment options. Thus, the development of new treatments for cLBP is urgently needed. The use of imagery to treat illness, including chronic pain, is one of the oldest medical practices. Although still unde ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
MT-125 for the Therapeutic Treatment of Glioblastoma
SBC: MYOSIN THERAPEUTICS INC. Topic: 102PROJECT SUMMARYAn area of significant unmet need is the treatment of glioblastoma (GBM), an aggressive, fast-growing and lethal brain cancer that represents 48% of all malignant brain tumors. Untreated, GBM is fatal within three months, and due to its high rate of recurrence and invasive nature, the current standard of care, consisting of safe maximal tumor resection, radiation therapy and chemoth ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline
SBC: SYNCHROHEALTH LLC Topic: NIAPROJECT SUMMARY Clinical Need: Sarcopenia and frailty represent significant and growing clinical challenges whose rates increase with age, and place patients at risk for functional decline, institutionalization, or death. Resistance exercises are strongly recommended in this age group to promote muscle regeneration and strength and are routinely a part of evidence-based home exercise programs pres ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration
SBC: CRIMSON BIOPHARM INC Topic: NCIPROJECT SUMMARY The epidermal growth factor receptor (EGFR) gene is mutated and/or amplified in majority of primary glioblastoma (GBM). While EGFR-mutant GBM cancer cells are dependent on EGFR signaling for survival, numerous small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to show efficacy in this disease. There are two main reasons for these failures: i) Many of these EGFR-TKIs ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health